CORAL SPRINGS, Florida, November 4, 2014 /PRNewswire/ --

Demand for cannaboid-CBD-based products rising in US as cannabis - medical marijuana movement continues forward. Sector being closely monitored as U.S. elections take place today. Cannabis Companies in focus today are: Earth Science Tech, Inc. (OTC: ETST), GW Pharmaceuticals plc (NASDAQ: GWPH), Growblox Sciences, Inc. (OTC: GBLX), Hemp, Inc. (OTC: HEMP) and Terra Tech Corp. (OTC: TRTC)

Earth Science Tech, Inc. (OTC: ETST) a unique biotechnology company focused on nutraceuticals, bioceuticals and dietary supplements, today announced it has entered stage 2 of research on the effectiveness of its Hemp Oil Enriched with CBD (Cannabidiol) on Immune Cells at the College of Mathematics and Science at the University of Central Oklahoma (UCO) with the assistant dean Dr. Wei Chen.As initially stated ETST will continue to strive in order to be at the forefront of all natural products to increase overall health and wellness for consumers worldwide. To this end ETST is going to continue to research various formulations using all natural products to obtain additional research, testing, studies and claims. Furthermore ETST looks forward to updating the market with the results of the immune cell testing in the near term. On another note and as previously stated, ETST is very encouraged with the positive preliminary test results on the effects of ETST Hemp Oil Enriched with CBD-Cannabidiol on Animal Breast Cancer Cells and on Normal Cells. ETST recently announced that the initial report from the Sponsored Research Agreement with the University of Central Oklahoma and its lead investigator Dr. Wei R. Chen showed the effects of its Hemp Oil Enriched with CBD-Cannabidiol (provided by Earth Science Tech, Inc.) on animal breast cancer cells and on normal cells. The results of this preliminary study indicate that with appropriate dose, in this case with ETST proprietary Hemp Oil Enriched with CBD-Cannabidiol dose, Hemp Oil Enriched with CBD-Cannabidiol can inhibit the proliferation of cancer cells more than that of normal cells. This purpose of the experiment with the University of Central Oklahoma and its lead investigator Dr. Wei R. Chen was to investigate the effects of ETST Hemp oil Enriched with CBD-Cannabidiol on animal breast cancer cells and on normal cells. If Hemp Oil Enriched with CBD-Cannabidiol has the same effect in vivo, it may help with cancer patients. However, further experiments are needed to investigate the effects of Hemp Oil Enriched with CBD-Cannabidiol on different cells, particularly on immune cells. Therefore ETST has begun testing with immune cells and is excited to see what the future may bring us and consumers worldwide. 

To read the full ETST press release, please click here:  http://www.financialnewsmedia.com/profiles/etst.html

On October 20, 2014, ETST entered into an Assignment of Patent Application with Dr. Wei R. Chen for assignment of a patent pending under Application number 62061577 entitled "Cannabidols Composition and Uses Thereof." ETST has secured, and was assigned, this new patent for Hemp Oil Enriched with CBD (Cannabidiol) and Hemp Oil Enriched with Proprietary Additives. Furthermore, ETST intends to invest upwards of $600,000.00 in order to secure and develop multiple patents and conduct clinical trials of the Cannabidol Compounds. The company feels this will allow it to be at the forefront of the Hemp Oil and CBD (Cannabidiol) markets. The company is currently working with Allen F. Bennett, P.A. of Bennett Intellectual Property. Dr Katz stated, "The research to date has shown better than expected results, as we continue to test and develop new products with our Hemp Oil Enriched with CBD. I am very pleased of the efforts and developments with Dr. Wei Chen and the College of Mathematics and Science at the University of Central Oklahoma (UCO). We hope to be able to make a significant impact in the wellness and nutrition markets." 

In other Cannabis News Happenings and Developments:  GW Pharmaceuticals plc (NASDAQ: GWPH), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced it has commenced a Phase 2/3 clinical trial of Epidiolex(R) (cannabidiol or CBD) for the treatment of Dravet syndrome, a rare and catastrophic treatment-resistant form of childhood epilepsy. "The results of our open-label trial of Epidiolex in children with Dravet syndrome have been very encouraging and we are excited to begin this important placebo-controlled clinical trial," stated Orrin Devinsky MD, Professor of Neurology, Neurosurgery, and Psychiatry at NYU School of Medicine, and Principal Investigator of the trial. "As one of the largest epilepsy centers in the country, our focus has always been to find new and innovative ways to treat and cure children with various forms of epilepsy," said Dr. Angus Wilfong, neurologist at Texas Children's Hospital.

Growblox Sciences, Inc. (OTCQB: GBLX) will host its first annual medical cannabis conference on November 14th. This premiere event, titled "Cannabinoid Science and Medicine: From Plant to Medicine," will start at 9:30 a.m on November 14, 2014, at the Condado Vanderbilt Hotel in San Juan, Puerto Rico. Co-sponsored by parent GB Sciences and GB Sciences Puerto Rico (GBPR), the event will be cohosted by Dr. Jose A. Franceschini, Chief Medical Officer of GBPR, and Dr. Andrea Small-Howard, Chief Science Officer of GB Sciences. "Education is the key to providing access for the hundreds of thousands of people around the world who suffer from Alzheimer's, Parkinson's, epilepsy, and so many other diseases that would benefit from pharmaceutical-grade cannabis products," says Dr. Small-Howard. "This educational event will benefit participants by arming them with scientific and medical facts that are not widely available."

Hemp, Inc. (OTCPink: HEMP) focuses on supplying services, products, and information related to the medical marijuana industry or to those who have an affinity for the medical marijuana industry. The company is designing a Website to offer news, issues, entertainment, and education on medical cannabis issues; developing proprietary software for transaction processing, MIS, loyalty program, and social network management; and producing video content that deals with current events as they relate to the industry and is available in high definition over the Internet. On Monday, HEMP closed up 11.32% on over 54 million shares traded.

Terra Tech Corp. (OTCQB: TRTC) recently announced that they have received a unanimous vote for approval of their Western Avenue dispensary location by the Las Vegas City Council. On October 29, 2014, the City Council voted to approve both the MediFarm SUP and the Compliance Permit. If MediFarm receives a State provisional registration certificate for a Medical Marijuana Dispensary at this location on November 3, 2014, then MediFarm will proceed with the last step for full licensure, a final review for a privileged business license in the City of Las Vegas. If succesful the company will begin construction at their Western Ave location and will open under the name Blum LV. MediFarm, LLC, a subsidiary of Terra Tech Corp., originally submitted its applications to the City of Las Vegas on July 23, 2014, to obtain a Special Use Permit (SUP) and Compliance Permit for a Medical Marijuana Dispensary to be located at 1921 Western Avenue in Las Vegas, Nevada. Issuance of the SUP demonstrates compliance with land use requirements and issuance of the Compliance Permit is required prior to the City issuing a business license. The Downtown Design Review Committee approved the building elevations and signage for MediFarm's dispensary at this location on August 26, 2014 and the City Planning Commission voted to recommend approval of the SUP on September 30, 2014. The City of Las Vegas Planning Department recommended approval of MediFarm's Compliance Permit with approval of the SUP.

FinancialNewsMedia.com is leading provider of third party publishing & news dissemination services. If you would like more information regarding our news coverage solutions, please visit http://www.financialnewsmedia.com for more details.  Get an edge on the market with our Premium News Alerts that are FREE for a limited time at http://www.financialnewsmedia.com/. Follow us on Facebook: http://www.facebook.com/financialnewsmedia and Twitter:  http://twitter.com/FNMgroup. 

DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNMG has been compensated one thousand four hundred dollars for news coverage of the current press release issued by Earth Science Tech, Inc. by the company. FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE. 

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Contact Information:
Company: FN Media Group, LLC
Contact email: editor@financialnewsmedia.com
U.S. Phone: +1(954)345-0611
URL: http://www.financialnewsmedia.com

SOURCE FN Media Group, LLC